Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders
Source: SeekingAlpha
2025-02-23 20:08:22 ET
Summary
- Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies.
- Today, KOD’s pipeline includes Phase 3 candidates for DR, RVO, and wet AMD, targeting an $18 billion TAM by 2028.
- The main catalyst to watch now is their upcoming pivotal data in 2026 that could lead to FDA approval by 2027.
- KOD also recently partnered up with Nona Biosciences to enhance its ability to develop multi-target, human monoclonal antibodies.
- From a valuation perspective, I also think KOD trades near cash value with a strong runway into 2026. So, I believe it’s a decent “Buy” at these levels.
Read the full article on Seeking Alpha
For further details see:
Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders
Kodiak Sciences Inc
NASDAQ: KOD
KOD Trading
9.34% G/L:
$37.82 Last:
1,171,040 Volume:
$34.77 Open:
KOD Latest News
March 26, 2026 09:53:26 am
AI, Biotech, and Defense Converge: Small Caps Chase Big Markets as Innovation Narrative Heats Up
March 26, 2026 06:00:00 am
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda(TM) (tarcocimab tedromer) Over Sham
March 09, 2026 10:06:30 am
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing
KOD Stock Data
$1,412,241,980
32,435,700
0.8%
39
N/A
Biotechnology & Life Sciences
Healthcare
US
Palo Alto
